Loading…
Provider of home health, hospice and private-duty nursing services, focused heavily on pediatric home care.
Provider of home health, hospice and private-duty nursing services, focused heavily on pediatric home care.
Paid mostly by state Medicaid programs, which set the hourly rates for nursing visits in children's homes, with Medicare paying set amounts for home health and hospice. Results therefore depend on state rate decisions and on how many nurses it can hire and keep. Bain Capital owned it before its 2021 listing.
Moat: narrow (scale, regulatory licence). Largest pediatric private-duty nursing provider in a heavily state-regulated, labor-constrained industry.
Headquarters: Atlanta, Georgia · Founded: 1999 · Employees: 35,500
Size Aveanna Healthcare (AVAH) is a United States Health Care company (Medical/Nursing Services) with a market value of $2.89B, the 1575th largest of 3,117 United States companies the cockpit tracks. Shares closed at $13.25 on 6 Nov 2026.
Performance Over six months the shares gained 96.6%, against +30.5% for the median peer and -1.1% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 19.5% over the last twelve months (peer median +4.1%); the operating margin is 11.4% (peer median 7.5%).
Valuation It trades at 15.4× forward earnings against a peer median of 40.1× (2nd cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.1 points above its cost of capital (11.7% WACC).
Short interest Short interest is 2.4% of the free float (15 Oct 2026).
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.60B | $2.43B | $2.02B | $1.90B | $1.79B |
| Revenue growth | — | +20% | +7% | +6% | — |
| Gross profit | $829M | $800M | $625M | $582M | $532M |
| EBITDA | $326M | $296M | $182M | $144M | $118M |
| Net income | $275M | $225M | -$10.9M | -$135M | -$662M |
| Free cash flow | $156M | $115M | $24.1M | $16.6M | -$60.4M |
| Capital expenditure | $9.81M | $7.45M | $6.32M | $6.12M | $12.0M |
| Total debt | $1.51B | $1.51B | $1.50B | $1.50B | $1.50B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Aveanna Healthcare AVAH | $2.89B | +97% | +20% | 11% | 15.4× | 13.4% |
| Addus HomeCare ADUS | $2.32B | +25% | +12% | 11% | 16.6× | 4.9% |
| Encompass Health EHC | $13.5B | +30% | +9% | 18% | 20.5× | 5.6% |
| BrightSpring Health Services BTSG | $13.4B | +22% | +23% | 4% | 28.3× | 24.2% |
| Pennant PNTG | $1.27B | +1% | +38% | 6% | 24.0× | 21.1% |
| Chemed CHE | $6.87B | +24% | +5% | 14% | 19.5× | 2.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AVAH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.2% | +8.3% | 11th highest of 21 |
| 6-month return | +96.6% | +30.5% | 4th highest of 20 |
| Distance from 52-week high | -9.9% | -15.2% | 9th highest of 21 |
| Revenue growth (TTM) | +19.5% | +4.1% | 4th highest of 21 |
| Operating margin | 11.4% | 7.5% | 4th highest of 21 |
| Forward P/E | 15.4× | 40.1× | 2nd cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 13.4% | 15.0% | 8th least demanding of 16 |
| Growth delivered (Del g) | +10.2% | +8.9% | 8th highest of 16 |
| Hurdle (Req g minus delivered) | +3.2 pp | +3.5 pp | 8th least demanding of 16 |
| ROIC minus cost of capital | +2.1 pp | -1.1 pp | 7th highest of 20 |
| EV / EBITDA | 13.2× | 12.9× | 6th most expensive of 12 |
| Net debt / EBITDA | 4.3× | 1.8× | 5th most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aveanna Healthcare AVAH | United States | $2.89B | +97% | +20% | 11% | 15.4× | 13.4% | +10.2% |
| Meinian Onehealth Healthcare 002044.SZ | China | $2.89B | -9% | -4% | 9% | 55.1× | 5.8% | +5.7% |
| Fameglow 3774.HK | Hong Kong | $3.19B | n/a | +36% | 11% | n/a | 48.8% | +48.4% |
| Pediatrix Medical MD | United States | $2.44B | +33% | +2% | 12% | 12.9× | -4.5% | +2.0% |
| Acadia Healthcare ACHC | United States | $3.44B | +47% | +4% | 10% | 18.7× | n/a | n/a |
| Dr. Lal PathLabs LALPATHLAB.NS | India | $3.50B | +26% | +17% | 24% | 51.5× | 32.2% | +11.8% |
| Addus HomeCare ADUS | United States | $2.32B | +25% | +12% | 11% | 16.6× | 4.9% | +13.2% |
| AddLife ALIF-B.ST | Sweden | $2.29B | +25% | +2% | 8% | 40.5× | 21.6% | +14.6% |
| NeoGenomics NEO | United States | $2.18B | +88% | +11% | -6% | 58.9× | n/a | n/a |
| Medicover MCOV-B.ST | Sweden | $4.14B | +36% | +6% | 7% | 38.3× | 20.8% | +20.2% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.99B | +5% | -3% | 7% | 31.7× | 6.7% | -6.1% |
| Dian Diagnostics 300244.SZ | China | $1.97B | +11% | -5% | 9% | 25.2× | 2.4% | -1.1% |
| Emeis EMEIS.PA | France | $1.94B | -30% | +4% | 3% | n/a | 21.3% | +8.5% |
| agilon health AGL | United States | $1.90B | +109% | 0% | -4% | 67.5× | n/a | n/a |
| GeneDx WGS | United States | $1.86B | +53% | +25% | -12% | 98.7× | n/a | n/a |
| Option Care Health OPCH | United States | $4.74B | +54% | +4% | 6% | 15.6× | 1.5% | +13.2% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 89.1× | 41.9% | +26.9% |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 103.7× | 56.0% | +8.9% |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | n/a | n/a | n/a |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 40.1× | 15.0% | -5.1% |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 15.8× | 1.7% | +7.7% |